Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 886371-79-5 | MDL No. : | MFCD07374898 |
Formula : | C7H6FNO2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | WVUMSXSSXWAGJM-UHFFFAOYSA-N |
M.W : | 155.13 | Pubchem ID : | 46311149 |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.14 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 35.47 |
TPSA : | 39.19 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.44 cm/s |
Log Po/w (iLOGP) : | 1.63 |
Log Po/w (XLOGP3) : | 1.14 |
Log Po/w (WLOGP) : | 1.43 |
Log Po/w (MLOGP) : | 0.76 |
Log Po/w (SILICOS-IT) : | 1.61 |
Consensus Log Po/w : | 1.32 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.79 |
Solubility : | 2.51 mg/ml ; 0.0162 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.56 |
Solubility : | 4.3 mg/ml ; 0.0277 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.37 |
Solubility : | 0.669 mg/ml ; 0.00432 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.69 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
INTERMEDIATE 23 Methyl 4-(3-iodo- lH-pyrazol- 1 -yl)picolinate To 3-iodo-lH-pyrazole (625 mg, 3.22 mmol) in DMSO (15 mL) at 0 C,was added sodium hydride (60% in mineral oil, 155 mg, 3.87 mmol). The reaction was stirred for 30 min before methyl 4-fluoropicolinate (500 mg, 3.22 mmol) was added and the reaction was stirred at 90 C for 4.5 h. The reaction mixture was quenched by the addition of water and the mixture was extracted with EtOAc. The combined organic extracts were dried over MgS04 and concentrated in vacuo. The crude mixture was purified by flash chromatography (ISCO Combiflash, 0-100%) EtOAc in hexanes) to afford methyl 4-(3-iodo-lH-pyrazol-l-yl)picolinate, as a colorless solid. LCMS calc. = 329.97; found = 329.88 (M+H)+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
84% | With methanol; sodium tetrahydroborate at 0 - 20℃; for 4h; | 199.1 Step-1 : Synthesis of (4-fluoropyridin-2-yl)methanol To a solution of methyl 4-fluoropyridine-2-carboxylate (500 mg, 3.22 mmol) in MeOH (15 mL) was added NaBHi (245 mg, 6.44 mmol) in portions at 0 °C and stirred at room temperature for 4 h. The reaction mixture was then quenched by the addition of water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford the title compound (420 mg, 84%) as a yellow solid. |
[ 475561-89-8 ]
Methyl 4-fluoro-1H-pyrrole-2-carboxylate
Similarity: 0.93
[ 475561-89-8 ]
Methyl 4-fluoro-1H-pyrrole-2-carboxylate
Similarity: 0.93
[ 475561-89-8 ]
Methyl 4-fluoro-1H-pyrrole-2-carboxylate
Similarity: 0.93
[ 475561-89-8 ]
Methyl 4-fluoro-1H-pyrrole-2-carboxylate
Similarity: 0.93